News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease
October 6, 2020
Reuters
Read Now
Press Release
Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease
October 6, 2020
Reuters
Read Now
News
Scribe Therapeutics launches to explore next-generation CRISPR technology
October 6, 2020
Chemical & Engineering News
Read Now
Press Release
Scribe Therapeutics launches to explore next-generation CRISPR technology
October 6, 2020
Chemical & Engineering News
Read Now
News
CRISPR startup Scribe Therapeutics lands big Biogen deal
October 6, 2020
San Francisco Business Times
Read Now
Press Release
CRISPR startup Scribe Therapeutics lands big Biogen deal
October 6, 2020
San Francisco Business Times
Read Now
News
Scribe: engineering CRISPR’s next generation
October 6, 2020
BioCentury
Read Now
Press Release
Scribe: engineering CRISPR’s next generation
October 6, 2020
BioCentury
Read Now